Gubra raises financial outlook for 2024 - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Kom igång: Så börjar du spara i fonder 2025 – bästa tipsen för att komma igång (stor guide)

Pressmeddelande

Gubra raises financial outlook for 2024

MFN Publicerad: 21 Aug 17:12
Gubra

Today, Gubra announces an upgrade to its full-year 2024 financial outlook. Organic revenue growth for the CRO business is now expected to be 23-28% (previously 15-20%) and adjusted EBIT-margin is expected to be 29-32% (previously 28-31%). For the Discovery & Partnerships business, the 2024 outlook is unchanged.

The upgrade to the CRO business follows high activity in the first half of 2024 and solid current trading and orderbook. The main growth driver is the Obesity area where Gubra is a leading provider of high-end preclinical Obesity services.

Outlook for 2024

Key ratioNew outlook for 2024Previous outlook for 2024*
CRO Segment  
Organic revenue growth y/y23-28%15-20%
Adjusted EBIT-margin29-32%28-31%
Discovery & Partnerships Segment  
Number of new partnerships per year1-21-2
Total costs (adjusted)DKK 160-170mDKK 160-170m
Total costs excl. Amylin asset (adjusted)DKK 115-125mDKK 115-125m

* Previous outlook announced 6 May 2024.

First half results 2024 will be published in Gubra’s half-year report 2024 on 22 August 2024.

Contacts at Gubra
Media: Sofia Pitt Boserup, [email protected], +45 4188 9586
Investors: Kristian Borbos, [email protected], +45 3080 8035

About Gubra
Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. In 2023, Gubra had approx. 220 employees and revenue of DKK 205 million. See www.gubra.dk for more information.

This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-21 17:12 CEST.

Attachments
Gubra raises financial outlook for 2024

Bifogade filer

Gubra raises financial outlook for 2024https://storage.mfn.se/4b435bfe-4408-4218-9741-769e7425c8e5/gubra-raises-financial-outlook-for-2024.pdf

Nyheter om Gubra

Läses av andra just nu

Om aktien Gubra

Senaste nytt